Publications by authors named "Ronald Stoller"

Claim this Profile
A
A phase 1 study of veliparib (ABT-888) plus weekly carboplatin and paclitaxel in advanced solid malignancies, with an expansion cohort in triple negative breast cancer (TNBC) (ETCTN 8620).
Monica K Malhotra, Shalu Pahuja, Brian F Kiesel, Leonard J Appleman, Fei Ding, Ronald G Stoller

Breast Cancer Res Treat· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast cancer.
Julia Manzo, Shannon Puhalla, Shalu Pahuja, Fei Ding, Yan Lin, Ronald Stoller

Cancer Chemother Pharmacol· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 study of safety, pharmacokinetics, and pharmacodynamics of tivantinib in combination with bevacizumab in adult patients with advanced solid tumors.
William F Maguire, John C Schmitz, Jonas Scemama, Ken Czambel, Yan Lin, Ronald Stoller

Cancer Chemother Pharmacol· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 study of veliparib (ABT-888), a poly (ADP-ribose) polymerase inhibitor, with carboplatin and paclitaxel in advanced solid malignancies.
Leonard J Appleman, Jan H Beumer, Yixing Jiang, Yan Lin, Fei Ding, Ronald Stoller

Cancer Chemother Pharmacol· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Results of a prospective phase 2 clinical trial of induction gemcitabine/capecitabine followed by stereotactic ablative radiation therapy in borderline resectable or locally advanced pancreatic adenocarcinoma.
Kimmen Quan, Philip Sutera, Karen Xu, Mark E Bernard, Steven A Burton, Ronald Stoller

Pract Radiat Oncol· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of veliparib in combination with gemcitabine.
Ronald Stoller, John C Schmitz, Fei Ding, Shannon Puhalla, Chandra P Belani

Cancer Chemother Pharmacol· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized Multicenter Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (DCF) Versus DCF Plus Growth Factor Support in Patients With Metastatic Gastric Adenocarcinoma: A Study of the US Gastric Cancer Consortium.
Manish A Shah, Yelena Y Janjigian, Ronald Stoller, Stephen Shibata, Margaret Kemeny

J Clin Oncol· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor Sonidegib (LDE225) in patients with advanced solid tumors.
Jordi Rodon, Hussein A Tawbi, Anne L Thomas, Ronald G Stoller, Christian P Turtschi

Clin Cancer Res· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Calcium carbonate does not affect imatinib pharmacokinetics in healthy volunteers.
Hussein Tawbi, Susan M Christner, Yan Lin, Matthew Johnson, Emily T Mowrey, Ronald Stoller

Cancer Chemother Pharmacol· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Calcium carbonate does not affect nilotinib pharmacokinetics in healthy volunteers.
Hussein A Tawbi, An L Tran, Susan M Christner, Yan Lin, Matthew Johnson, Ronald Stoller

Cancer Chemother Pharmacol· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes with FOLFIRINOX for borderline resectable and locally unresectable pancreatic cancer.
Brian A Boone, Jennifer Steve, Alyssa M Krasinskas, Amer H Zureikat, Barry C Lembersky, Ronald G Stoller

J Surg Oncol· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mechanism-based model characterizing bidirectional interaction between PEGylated liposomal CKD-602 (S-CKD602) and monocytes in cancer patients.
Huali Wu, Ramesh K Ramanathan, Beth A Zamboni, Sandra Strychor, Suresh Ramalingam, Ronald G Stoller

Int J Nanomedicine· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I and pharmacokinetic study of dasatinib and cetuximab in patients with advanced solid malignancies.
Athanassios Argiris, Trevor M Feinstein, Lin Wang, Tianbing Yang, Shruti Agrawal, Ronald G Stoller

Invest New Drugs· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II study of irinotecan and cetuximab given every 2 weeks as second-line therapy for advanced colorectal cancer.
Benedito A Carneiro, Ramesh K Ramanathan, Marwan G Fakih, Smitha S Krishnamurthi, Barry C Lembersky, Ronald G Stoller

Clin Colorectal Cancer· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I and pharmacokinetic study of oral 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in the treatment of advanced-stage solid cancers: a California Cancer Consortium Study.
Joseph Chao, Timothy W Synold, Robert J Morgan, Charles Kunos, Jeff Longmate, Ronald G Stoller

Cancer Chemother Pharmacol· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetics of pegylated liposomal CKD-602 (S-CKD602) in patients with advanced malignancies.
Huali Wu, Ramesh K Ramanathan, Beth A Zamboni, Sandra Strychor, Suresh Ramalingam, Ronald G Stoller

J Clin Pharmacol· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bidirectional pharmacodynamic interaction between pegylated liposomal CKD-602 (S-CKD602) and monocytes in patients with refractory solid tumors.
William C Zamboni, Lauren J Maruca, Sandra Strychor, Beth A Zamboni, Suresh Ramalingam, Ronald G Stoller

J Liposome Res· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The spectrum of coincident entities with small lymphocytic lymphoma/chronic lymphocytic leukemia (SLL/CLL) diagnosed by cytology.
Hannah A Kastenbaum, Walid E Khalbuss, Raymond E Felgar, Ronald Stoller, Sara E Monaco

Cytojournal· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I and pharmacokinetic study of pegylated liposomal CKD-602 in patients with advanced malignancies.
William C Zamboni, Suresh Ramalingam, David M Friedland, Robert P Edwards, Ronald G Stoller

Clin Cancer Res· February 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I study of 17-allylamino-17-demethoxygeldanamycin combined with paclitaxel in patients with advanced solid malignancies.
Suresh S Ramalingam, Merrill J Egorin, Ramesh K Ramanathan, Scot C Remick, Rachel P Sikorski, Ronald G Stoller

Clin Cancer Res· June 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies.
Suresh S Ramalingam, Robert A Parise, Ramesh K Ramanathan, Theodore F Lagattuta, Lori A Musguire, Ronald G Stoller

Clin Cancer Res· June 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I and pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with refractory advanced cancers.
Ramesh K Ramanathan, Merrill J Egorin, Julie L Eiseman, Suresh Ramalingam, David Friedland, Ronald G Stoller

Clin Cancer Res· March 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Spontaneous CD4+ T cell responses against TRAG-3 in patients with melanoma and breast cancers.
Bratislav Janjic, Pedro Andrade, Xiao-Fei Wang, Julien Fourcade, Christine Almunia, Ronald Stoller

J Immunol· August 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II study of rubitecan, an oral camptothecin in patients with advanced colorectal cancer who have failed previous 5-fluorouracil based chemotherapy.
Hitendra Patel, Ronald Stoller, Miklos Auber, Douglas Potter, Chao Cai

Invest New Drugs· July 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Final results of a placebo-controlled study of filgrastim in small-cell lung cancer: exploration of risk factors for febrile neutropenia.
Jeffrey Crawford, John A Glaspy, Ronald G Stoller, Dianne K Tomita, Martha E Vincent

Support Cancer Ther· October 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis